|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2000, Vol. 96, No. 4, pp. 1274-1279
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
B7-2-positive myeloma: incidence, clinical characteristics,
prognostic significance, and implications for tumor immunotherapy
Belinda Pope,
Ross
D. Brown,
John Gibson,
Edna Yuen, and
Doug Joshua
From the Institute of Haematology, Royal Prince
Alfred Hospital, Sydney, Australia.
Deficiencies in B7:CD28 costimulation are considered to be one of
the major causes of the failure to generate a tumor-specific immune
response. Up-regulating the expression of the B7 molecules on malignant
B cells has been shown to stimulate cytotoxic T cells. Plasma cells
from patients with myeloma express a tumor-specific idiotype but lack
CD80 (B7-1) and have a variable expression of CD86 (B7-2). This study
has identified the incidence and clinical significance of high CD86
expression on plasma cells at diagnosis and studied the ability of
trimeric human CD40 ligand (huCD40LT) to up-regulate the expression of
the B7 family on malignant plasma cells. CD86 expression on plasma
cells was increased in 54% of the patients studied at diagnosis
(n = 35) and was associated with a significantly shorter survival
(median, 28 versus 57 months;  2 = 4.6;
P = .03) and a higher tumor load (patients with more than 50% bone marrow plasma cells, 47% versus 6%;
2 = 7.2; P = .005). CD86 expression was
highest on immature and primitive plasma cells (CD38++,
CD45+) of both patients and controls and was associated
with a CD40+, CD20+, CD19 ,
CD138+ phenotype. The shortened survival was associated
with high CD86 only on mature (CD38++, CD45)
plasma cells (2 = 7.6; P = .006). There
was no significant correlation between high CD86 and other known
prognostic markers, including serum  2-microglobulin,
serum thymidine kinase, and labeling index. The addition of huCD40LT to
short-term cultures up-regulated both CD80 and CD86 expression on B
cells (CD19+) and CD80 on plasma cells
(CD38++), but did not up-regulate CD86 expression on plasma
cells. Thus, B7-2-positive myeloma consists of a subgroup of
patients with a relatively poor prognosis, and CD40LT may be useful in
immunotherapy protocols because it up-regulates CD80 expression on
malignant plasma cells without inducing B7-2-positive myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. J. Bahlis, A. M. King, D. Kolonias, L. M. Carlson, H. Y. Liu, M. A. Hussein, H. R. Terebelo, G. E. Byrne Jr, B. L. Levine, L. H. Boise, et al.
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Blood,
June 1, 2007;
109(11):
5002 - 5010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tirapu, E. Huarte, C. Guiducci, A. Arina, M. Zaratiegui, O. Murillo, A. Gonzalez, C. Berasain, P. Berraondo, P. Fortes, et al.
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
Cancer Res.,
February 15, 2006;
66(4):
2442 - 2450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Ellyard, D. T. Avery, T. G. Phan, N. J. Hare, P. D. Hodgkin, and S. G. Tangye
Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow
Blood,
May 15, 2004;
103(10):
3805 - 3812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Heider, I. Zavrski, C. Jakob, C. Fleissner, O. Sezer, A. C. W. Zannettino, B. Pan, A. N. Farrugia, G. J. Atkins, and L. B. To
Identification and Clinical Relevance of Receptor Activator of Nuclear Factor {kappa}B Ligand Expression of Myeloma Cells
Cancer Res.,
January 15, 2004;
64(2):
773 - 775.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Wei and S Juneja
Bone marrow immunohistology of plasma cell neoplasms
J. Clin. Pathol.,
June 1, 2003;
56(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. San Miguel, J. Almeida, G. Mateo, J. Blade, C. Lopez-Berges, D. Caballero, J. Hernandez, M. J. Moro, J. Fernandez-Calvo, J. Diaz-Mediavilla, et al.
Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
Blood,
March 1, 2002;
99(5):
1853 - 1856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M.-Y. Sze, G. Giesajtis, R. D. Brown, M. Raitakari, J. Gibson, J. Ho, A. G. Baxter, B. Fazekas de St Groth, A. Basten, and D. E. Joshua
Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment
Blood,
November 1, 2001;
98(9):
2817 - 2827.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
